Scoop: Smart Immune targets $54M Series A to advance T cell progenitor therapy: #Jefferies23
French biotech Smart Immune has raised more than half of its roughly €50 million ($54 million) target in an ongoing Series A round, with an eye to completing Phase I/II development for its lead cell therapy program in two different indications, Endpoints News has learned.
The Series A should be completed in early 2024, CEO Karine Rossignol told Endpoints on the sidelines of the Jefferies healthcare meeting Tuesday. “We need to have a mix of European investors, US investors and ideally pharma investors,” Rossignol said.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.